Undertreatment of osteoporosis in men

Archives of Internal Medicine

Volumn 165, Issue 2, 2005, Pages 241-

  Meryn, Siegfried ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PARATHYROID HORMONE; TESTOSTERONE;

BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; FEMUR NECK; FRAGILITY FRACTURE; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; HYPOGONADISM; LETTER; MEDICAL DECISION MAKING; OSTEOLYSIS; OSTEOPOROSIS; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; UNITED STATES;

AGED; BONE DENSITY; DIPHOSPHONATES; FRACTURES, SPONTANEOUS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OSTEOPOROSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; UNITED STATES;

EID: 19944433247     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.165.2.241     Document Type: Letter

References (5)

1. Stafford RS, Drieling RL, Hersh AL. National Trends in Osteoporosis Visits and Osteoporosis Treatment: 1988-2003. Arch Intern Med. 2004;164:1525-1530.
2. National Institutes of Health; Osteoporosis and Related Bone Diseases National Resource Center. Fast facts on Osteoporosis. February 2004. Available at: http://www.osteo.org/newfile.asp?doc = fast&rdoctitle=Fast+ Facts+on+Osteporosis+doctype=HTML+Fact+Sheet. Accessed July 2, 2004.
3. Olszynski WP, Shawn Davison K, Adachi JD, et al. Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther. 2004;26:15-28.
4. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of Osteoporosis in men. N Engl J Med. 2000;343:604-610.
5. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with Osteoporosis. N Engl J Med. 2003;349:1216-1226.